← SynDRA
MK-0812
SynDRA canonical compound SYN0038071 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | CCR2 |
|---|
| Mechanism of action | CCK receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- CCK receptor antagonist
- CCR2 ANTAGONIST
- C-C chemokine receptor type 2 antagonist
- CC chemokine receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADGRF1
- HTR2A
- GPR35
- HDAC6
- HRH1
- HRH2
- HRH3
- HRH4
- HTR1A
- HTR1B
- HTR1E
- HTR2B
- ADRA1A
- HTR6
- OPRD1
- OPRK1
- OPRM1
- S1PR1
- SIGMAR1
- SLC6A3
- SLC6A4
- TMEM97
- GPR119
- GLP1R
- FPR2
- FFAR4
- ADRA1B
- ADRA1D
- ADRA2A
- ADRA2C
- ADRB1
- ADRB2
- ADRB3
- AGTR1
- APLNR
- C5AR1
- CHRM1
- CHRM2
- CHRM3
- CHRM5
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- Mk0812
- C-6448
- MK-812
- CCR2 antagonist (rheumatoid arthritis/multiple sclerosis), Merck
- MK0812
- C24H34F3N3O3
- MTMDXAIUENDNDL-RJSMDTJLSA-N
- MFCD11977737
- GTPL9048
- orb1679026
- SCHEMBL2209755
- SCHEMBL30046631
- EX-A939
- GLXC-90281
- BDBM50077906
- AKOS025401941
- CS-0344
- FM32516
- NCGC00378765-02
- NCGC00378765-03
- NCGC00378765-04
- NCGC00378765-05
- AC-27464
- AS-32918
- HY-50669
- BRD-K14175878-001-01-6
- MFCD30489753
- CS-5928
- Tox21_300263
- DA-65495
- AKOS032944982
- C28H40F3N3O7
- NCGC00254109-01
- CAS-851916-42-2
- orb1308034
- MK-0812 Succinate
- SCHEMBL2209861
- MS-30497
Look up MK-0812 in the interactive SynDRA portal →